BioSpace News Archive

Novartis' office building in Marburg, Germany

Policy

Novartis Latest to Join Lawsuits Against IRA Drug Negotiation Program

The Swiss pharmaceutical company filed a suit Friday joining a growing group of legal complaints by Big Pharma seeking to block the Inflation Reduction Act’s Drug Price Negotiation Program.

September 5, 2023

·

2 min read

·

Tristan Manalac

Pictured: Building with an Illumina sign in front/

Business

Illumina Taps Agilent Exec as New CEO Amid Company’s Daunting Challenges

Former Agilent Technologies executive Jacob Thaysen will take the reins later this month replacing CEO Francis deSouza, who stepped down in June following a proxy fight with activist investor Carl Icahn.

September 5, 2023

·

2 min read

·

Kate Goodwin

Pictured: An entrance to Purdue University campus/

Feeder Programs First Step in Bringing More Diversity to Pharma

Purdue University and Eli Lilly begin one of the only scholarship programs in the country aimed at seniors in high school, while other companies launch similar initiatives for graduate students.

September 5, 2023

·

5 min read

·

Mollie Barnes

Pictured: Graphic of stock data overlaid over stac

Why Biopharma Companies Buy Stock in One Another

Biopharma companies buying stock in one another did not used to be an unusual practice, but experts told BioSpace this is becoming less common due to greater market volatility.

September 5, 2023

·

3 min read

·

Ana Mulero

Pictured: 3D illustration of antibody-drug conjugates with their toxic payloads

Drug Development

Genmab, Seagen Notch Late-Stage Victory in Metastatic Cervical Cancer

The companies are moving closer to traditional approval for the antibody-drug conjugate Tivdak, which met its primary endpoint for overall survival in an interim analysis.

September 5, 2023

·

2 min read

·

Tristan Manalac

Pictured: A funnel of American cash/iStock, ardasa

Healthcare Industry Poised to Profit from New Alzheimer’s Treatments

In addition to massive revenues predicted for their developers, Leqembi—and possibly donanemab, if approved—should bring in substantial dollars to the healthcare industry.

September 5, 2023

·

7 min read

·

Kate Goodwin

Pictured: Illustration of students sitting at a ta

Community Colleges Help Address Skills Gap

Half of entry-level jobs in the U.S. life sciences require skills considered middle and lower level that could be filled by people with less than a four-year degree, according to a recent report on life sciences workforce trends.

September 5, 2023

·

3 min read

·

Jennifer Markarian

Pictured: Novartis Building/iStock, JHVE Photo

Business

Novartis Confirms Sandoz Spin-Off Plans, Sets Oct. 4 Completion Date

The company Tuesday posted Sandoz’s financial performance for the first half of 2023, as it looks to secure the approval of shareholders this month for the generics and biosimilars spin-off.

September 5, 2023

·

2 min read

·

Tristan Manalac

Pictured: A pharmacist looking at a tablet in fron

Policy

Medicare Negotiations Unlikely to Cause Financial Losses—At Least for Now

With several of the first 10 selected drugs facing patent expirations and generic competition, the drug price negotiations dictated by the IRA may not greatly affect revenues. But that could change quickly.

September 5, 2023

·

4 min read

·

Roxanne Nelson

Business

Aesthetic Medical International Reports First Half of 2023 Unaudited Financial Results

Aesthetic Medical International Holdings Group Limited, a leading provider of aesthetic medical services in China, announced its unaudited financial results for the six months ended June 30, 2023.

September 5, 2023

·

18 min read